22 Liver Cancer Clinical Trials in Houston, NC (2026)

Q: How do I join a clinical trial in Houston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you.

Recruiting Liver Cancer Studies in Houston

NCT05179486Recruiting

Molecular Epidemiology of Biliary Tree Cancers

This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree canc...

Houston, NC1,500 participantsM.D. Anderson Cancer Center

View Study Details

NCT06427941Recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monother...

Houston, NC392 participantsBeOne Medicines

View Study Details

NCT06795022Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced o...

Houston, NC304 participantsAstraZeneca

View Study Details

NCT07176650Recruiting

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in...

Houston, NC246 participantsShanghai Henlius Biotech

View Study Details

NCT04906434Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

This is an open-label phase 1 study with an escalation part and an expansion part....

Houston, NC200 participantsAbbisko Therapeutics Co, Ltd

View Study Details

NCT05797805Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least on...

Houston, NC178 participantsIterion Therapeutics

View Study Details

NCT05727176Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CC...

Houston, NC120 participantsTaiho Oncology, Inc.

View Study Details

NCT05143619Recruiting

Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching ...

Houston, NC100 participantsM.D. Anderson Cancer Center

View Study Details

NCT07164313Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma ...

Houston, NC100 participantsZymeworks BC Inc.

View Study Details

NCT06858735Recruiting

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 20...

Houston, NC60 participantsM.D. Anderson Cancer Center

View Study Details

NCT07116486Recruiting

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imagin...

Houston, NC60 participantsM.D. Anderson Cancer Center

View Study Details

NCT06501625Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in particip...

Houston, NC52 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT03897543Recruiting

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with ...

Houston, NC48 participantsAbivax S.A.

View Study Details

NCT07010315Recruiting

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

To develop and test liver cancer prevention educational material....

Houston, NC40 participantsM.D. Anderson Cancer Center

View Study Details

NCT06698250Recruiting

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic eﬀect when combined with checkpoint based immunotherapeutic treatment of pat...

Houston, NC40 participantsAnwaar Saeed

View Study Details

NCT06160752Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including un...

Houston, NC40 participantsTyra Biosciences, Inc

View Study Details

NCT06439485Recruiting

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma....

Houston, NC25 participantsM.D. Anderson Cancer Center

View Study Details

NCT05185505Recruiting

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receivi...

Houston, NC24 participantsThe Methodist Hospital Research Institute

View Study Details

NCT05967182Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to tre...

Houston, NC24 participantsM.D. Anderson Cancer Center

View Study Details

NCT04715191Recruiting

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cell...

Houston, NC24 participantsBaylor College of Medicine

View Study Details

NCT04134559Recruiting

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN...

Houston, NC18 participantsAllison O'Neill, MD

View Study Details

NCT04380545Recruiting

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed b...

Houston, NC15 participantsM.D. Anderson Cancer Center

View Study Details

About Liver Cancer Clinical Trials in Houston

Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.

There are currently 22 liver cancer clinical trials recruiting participants in Houston, NC. These studies are seeking a combined 3,610 participants. Research is being sponsored by M.D. Anderson Cancer Center, BeOne Medicines, AstraZeneca and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Liver Cancer Clinical Trials in Houston — FAQ

Are there liver cancer clinical trials in Houston?

Yes, there are 22 liver cancer clinical trials currently recruiting in Houston, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What liver cancer treatments are being tested?

The 22 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.

Data updated July 13, 2026 from ClinicalTrials.gov